| CEBPA |
U937 (adult acute monocytic leukemia) |
bio |
Permissive
Robust
|
Homo sapiens |
GSE29195
...
|
MA0019.1
...
|
| CEBPA |
U937 (adult acute monocytic leukemia) |
dmso |
Permissive
Robust
|
Homo sapiens |
GSE29195
...
|
MA0019.1
...
|
| CEBPA |
B-cells |
Estradiol for 18h |
Permissive
Robust
|
Mus musculus |
GSE52373
...
|
MA0019.1
...
|
| CEBPA |
3T3-L1-derived adipocytes |
0.1% DMSO (Vehicle) for 1 hour |
Permissive
Robust
|
Mus musculus |
GSE49423
...
|
MA0019.1
...
|
| CEBPA |
3T3-L1-derived adipocytes |
1 μM rosiglitazone / 0.1% DMSO for 1 hour |
Permissive
Robust
|
Mus musculus |
GSE49423
...
|
MA0019.1
...
|
| CEBPA |
HepG2 (hepatoblastoma) |
none |
Permissive
Robust
|
Homo sapiens |
GSE25021
...
|
MA0019.1
...
|
| CEBPA |
liver |
0 hours after partial hepatectomy |
Permissive
Robust
|
Mus musculus |
GSE42321
...
|
MA0019.1
...
|
| CEBPA |
liver |
3 hours after partial hepatectomy |
Permissive
Robust
|
Mus musculus |
GSE42321
...
|
MA0019.1
...
|
| CEBPA |
liver |
8 hours after partial hepatectomy |
Permissive
Robust
|
Mus musculus |
GSE42321
...
|
MA0019.1
...
|
| CEBPA |
liver |
16 hours after partial hepatectomy |
Permissive
Robust
|
Mus musculus |
GSE42321
...
|
MA0019.1
...
|
| CEBPA |
liver |
24 hours after partial hepatectomy |
Permissive
Robust
|
Mus musculus |
GSE42321
...
|
MA0019.1
...
|
| CEBPA |
liver |
36 hours after partial hepatectomy |
Permissive
Robust
|
Mus musculus |
GSE42321
...
|
MA0019.1
...
|
| CEBPA |
liver |
48 hours after partial hepatectomy |
Permissive
Robust
|
Mus musculus |
GSE42321
...
|
MA0019.1
...
|
| CEBPA |
liver |
168 hours after partial hepatectomy |
Permissive
Robust
|
Mus musculus |
GSE42321
...
|
MA0019.1
...
|
| CEBPA |
peritoneal macrophages |
no treatment |
Permissive
Robust
|
Mus musculus |
GSE46494
...
|
MA0019.1
...
|
| CEBPA |
peritoneal macrophages |
100 ng/ml Kdo2-LipidA 1 hr |
Permissive
Robust
|
Mus musculus |
GSE46494
...
|
MA0019.1
...
|
| CEBPA |
peritoneal macrophages |
no treatment |
Permissive
Robust
|
Mus musculus |
GSE46494
...
|
MA0019.1
...
|
| CEBPA |
peritoneal macrophages |
100 ng/ml Kdo2-LipidA 1 hr |
Permissive
Robust
|
Mus musculus |
GSE46494
...
|
MA0019.1
...
|
| CEBPA |
peritoneal macrophages |
no treatment |
Permissive
|
Mus musculus |
GSE46494
...
|
MA0019.1
...
|
| CEBPA |
macrophages |
none |
Permissive
Robust
|
Mus musculus |
GSE48759
...
|
MA0019.1
...
|
| CEBPA |
macrophages |
Kdo2 Lipid A (KLA) 1h |
Permissive
Robust
|
Mus musculus |
GSE48759
...
|
MA0019.1
...
|
| CEBPA |
BV-2 (brain microglial cells) |
wt human Htt overexpression |
Permissive
Robust
|
Mus musculus |
GSE54443
...
|
MA0019.1
...
|
| CEBPA |
BV-2 (brain microglial cells) |
mutant human Htt overexpression |
Permissive
Robust
|
Mus musculus |
GSE54443
...
|
MA0019.1
...
|
| CEBPA |
3T3-L1-derived adipocytes |
none |
Permissive
Robust
|
Mus musculus |
GSE56745
...
|
MA0019.1
...
|
| CEBPA |
C10 (pre-B-cells) |
0.1% ethanol as control sample |
Permissive
Robust
|
Mus musculus |
GSE53362
...
|
MA0019.1
...
|
| CEBPA |
C10 (pre-B-cells) |
100 nM of beta-estradiol + 10 nM of IL-3 and CSF-1 |
Permissive
Robust
|
Mus musculus |
GSE53362
...
|
MA0019.1
...
|
| CEBPA |
C10 (pre-B-cells) |
100 nM of beta-estradiol + 10 nM of IL-3 and CSF-1 |
Permissive
Robust
|
Mus musculus |
GSE53362
...
|
MA0019.1
...
|
| CEBPA |
C10 (pre-B-cells) |
100 nM of beta-estradiol + 10 nM of IL-3 and CSF-1 |
Permissive
Robust
|
Mus musculus |
GSE53362
...
|
MA0019.1
...
|
| CEBPA |
C10 (pre-B-cells) |
100 nM of beta-estradiol + 10 nM of IL-3 and CSF-1 |
Permissive
Robust
|
Mus musculus |
GSE53362
...
|
MA0019.1
...
|
| CEBPA |
C10 (pre-B-cells) |
100 nM of beta-estradiol + 10 nM of IL-3 and CSF-1 |
Permissive
Robust
|
Mus musculus |
GSE53362
...
|
MA0019.1
...
|
| CEBPA |
C10 (pre-B-cells) |
100 nM of beta-estradiol + 10 nM of IL-3 and CSF-1 |
Permissive
Robust
|
Mus musculus |
GSE53362
...
|
MA0019.1
...
|
| CEBPA |
C10 (pre-B-cells) |
100 nM of beta-estradiol + 10 nM of IL-3 and CSF-1 |
Permissive
Robust
|
Mus musculus |
GSE53362
...
|
MA0019.1
...
|
| CEBPA |
X18.1.1 (acute myeloid leukemia) |
PuER |
Permissive
Robust
|
Mus musculus |
GSE63317
...
|
MA0019.1
...
|
| CEBPA |
hepatocytes |
cebpa KO |
Permissive
Robust
|
Mus musculus |
GSE65167
...
|
MA0019.1
...
|
| CEBPA |
liver |
Trib1_LSKO |
Permissive
Robust
|
Mus musculus |
GSE70716
...
|
MA0019.1
...
|
| CEBPA |
liver |
AAV_Null |
Permissive
Robust
|
Mus musculus |
GSE70716
...
|
MA0019.1
...
|
| CEBPA |
liver |
AAV_Cebpa |
Permissive
Robust
|
Mus musculus |
GSE70716
...
|
MA0019.1
...
|
| CEBPA |
B-cells |
Cebpa18h |
Permissive
Robust
|
Mus musculus |
GSE71215
...
|
MA0019.1
...
|
| CEBPA |
bone marrow-derived mesenchymal stem cells |
osteogenic media day 7 |
Permissive
Robust
|
Mus musculus |
GSE79813
...
|
MA0019.1
...
|
| CEBPA |
bone marrow-derived mesenchymal stem cells |
adipose media day 7 |
Permissive
Robust
|
Mus musculus |
GSE79813
...
|
MA0019.1
...
|
| CEBPA |
brown preadipocytes |
Pparg-flox/flox |
Permissive
Robust
|
Mus musculus |
GSE74189
...
|
MA0019.1
...
|
| CEBPA |
brown preadipocytes |
Pparg-flox/flox |
Permissive
Robust
|
Mus musculus |
GSE74189
...
|
MA0019.1
...
|
| CEBPA |
brown preadipocytes |
Pparg-flox/flox |
Permissive
Robust
|
Mus musculus |
GSE74189
...
|
MA0019.1
...
|
| CEBPA |
brown adipocytes |
Pparg-flox/flox |
Permissive
Robust
|
Mus musculus |
GSE74189
...
|
MA0019.1
...
|
| CEBPA |
brown preadipocytes |
GR KO |
Permissive
Robust
|
Mus musculus |
GSE76619
...
|
MA0019.1
...
|
| CEBPA |
brown adipocytes |
day0 |
Permissive
|
Mus musculus |
GSE83757
...
|
MA0019.1
...
|
| CEBPA |
brown adipocytes |
day6 |
Permissive
Robust
|
Mus musculus |
GSE83757
...
|
MA0019.1
...
|
| CEBPA |
SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive) |
RUNX1-EVI1 KD after 10 days |
Permissive
Robust
|
Homo sapiens |
GSE87283
...
|
MA0019.1
...
|
| CEBPA |
bone marrow-derived macrophages |
cells differentiated in the presence of MCSF |
Permissive
Robust
|
Mus musculus |
GSE106705
...
|
MA0019.1
...
|
| CEBPA |
bone marrow-derived macrophages |
cells differentiated in the presence of MCSF (1h IL4) |
Permissive
Robust
|
Mus musculus |
GSE106705
...
|
MA0019.1
...
|
| CEBPA |
SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive) |
Treatment: estradiol; Genotype: inducible version of CEBPA (C/EBPalpha-ER); |
Permissive
Robust
|
Homo sapiens |
GSE102697
...
|
MA0019.1
...
|
| CEBPA |
SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive) |
Treatment: ethanol; Genotype: inducible version of CEBPA (C/EBPalpha-ER); |
Permissive
Robust
|
Homo sapiens |
GSE102697
...
|
MA0019.1
...
|
| CEBPA |
SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive) |
Treatment: ethanol; Genotype: SKH1; |
Permissive
|
Homo sapiens |
GSE102697
...
|
MA0019.1
...
|
| CEBPA |
SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive) |
Treatment: estradiol; Genotype: SKH1; |
Permissive
|
Homo sapiens |
GSE102697
...
|
MA0019.1
...
|
| CEBPA |
Kasumi-1 (acute myeloblastic leukemia) |
Treatment: estradiol; Genotype: inducible version of CEBPA (C/EBPalpha-ER); |
Permissive
Robust
|
Homo sapiens |
GSE102697
...
|
MA0019.1
...
|
| CEBPA |
Kasumi-1 (acute myeloblastic leukemia) |
Treatment: ethanol; Genotype: inducible version of CEBPA (C/EBPalpha-ER); |
Permissive
Robust
|
Homo sapiens |
GSE102697
...
|
MA0019.1
...
|
| CEBPA |
Kasumi-1 (acute myeloblastic leukemia) |
Treatment: ethanol; Genotype: Kkasumi1; |
Permissive
|
Homo sapiens |
GSE102697
...
|
MA0019.1
...
|
| CEBPA |
Kasumi-1 (acute myeloblastic leukemia) |
Treatment: estradiol; Genotype: Kkasumi1; |
Permissive
|
Homo sapiens |
GSE102697
...
|
MA0019.1
...
|
| CEBPA |
MA9 transformed mouse leukemia |
Treatment: none Genotype: MLL-AF9 fusion |
Permissive
Robust
|
Mus musculus |
GSE100758
...
|
MA0019.1
...
|
| CEBPA |
MA9 transformed mouse leukemia |
Treatment: LSD1 inhibitor GSK-LSD1 Genotype: MLL-AF9 fusion |
Permissive
Robust
|
Mus musculus |
GSE100758
...
|
MA0019.1
...
|
| CEBPA |
line-bone marrow untransformed myeloid progenitors |
Strain: C57BL/6 Treatment: Stem cell (10ng/mL IL3, 10ng/mL IL6 100mg/mL SCF) for 7 days |
Permissive
Robust
|
Mus musculus |
GSE103446
...
|
MA0019.1
...
|
| CEBPA |
HMM (HOXA9 transormed myeloblasts) |
Genotype: HOXA9/MEIS1-transformed Treament: culture conditions Myeloid (10ng/mL IL3) + 100nM 4OHT for 25 -31 days Source: in- bone marrow |
Permissive
Robust
|
Mus musculus |
GSE103446
...
|
MA0019.1
...
|
| CEBPA |
HMM (HOXA9 transormed myeloblasts) |
Genotype: HOXA9 inactivation Treatment: culture conditions Myeloid (10ng/mL IL3) + 4OHT for 25 -31 days wash off Source: Lin- bone marrow |
Permissive
Robust
|
Mus musculus |
GSE103446
...
|
MA0019.1
...
|
| CEBPA |
CFU-M |
Genotype: wildtype, cell markers Lin- Sca1- cKit+ CD150- CD41- FcgRII/III(hi) CD115+ Tissue: bone marrow |
Permissive
Robust
|
Mus musculus |
GSE89767
...
|
MA0019.1
...
|
| CEBPA |
preGM |
Genotype: wildtype, cell markers Lin-, Sca-1-, ckit+, CD150-, CD105- Tissue: bone marrow |
Permissive
Robust
|
Mus musculus |
GSE89767
...
|
MA0019.1
...
|
| CEBPA |
CFU-G |
Genotype: wildtype, cell markers Lin- Sca1-cKit+ CD150- CD41- FcgRII/III(hi) CD115- Tissue: bone marrow |
Permissive
Robust
|
Mus musculus |
GSE89767
...
|
MA0019.1
...
|
| CEBPA |
MLL-AF9 Leukemic Cells |
Genotype: wildtype Strain: C57BL/6 Treatment: Ethanol |
Permissive
Robust
|
Mus musculus |
GSE120063
...
|
MA0019.1
...
|
| CEBPA |
MLL-AF9 Leukemic Cells |
Genotype: C1B knockout Strain: C57BL/6 Treatment: treated with 10-7M B-estradiol daily for two days (48 hours) |
Permissive
Robust
|
Mus musculus |
GSE120063
...
|
MA0019.1
...
|
| CEBPA |
THP-1 (acute monocytic leukemia) |
Treatment: 0.1 % EtOH for 2 hrs |
Permissive
Robust
|
Homo sapiens |
GSE124032
...
|
MA0019.1
...
|
| CEBPA |
THP-1 (acute monocytic leukemia) |
Treatment: 100 nM 1,25(OH)2D3 for 2 hrs |
Permissive
Robust
|
Homo sapiens |
GSE124032
...
|
MA0019.1
...
|
| CEBPA |
THP-1 (acute monocytic leukemia) |
Treatment: 0.1 % EtOH for 8 hrs |
Permissive
Robust
|
Homo sapiens |
GSE124032
...
|
MA0019.1
...
|
| CEBPA |
THP-1 (acute monocytic leukemia) |
Treatment: 100 nM 1,25(OH)2D3 for 8 hrs |
Permissive
Robust
|
Homo sapiens |
GSE124032
...
|
MA0019.1
...
|
| CEBPA |
THP-1 (acute monocytic leukemia) |
Treatment: 0.1 % EtOH for 24 hrs |
Permissive
Robust
|
Homo sapiens |
GSE124032
...
|
MA0019.1
...
|
| CEBPA |
THP-1 (acute monocytic leukemia) |
Treatment: 100 nM 1,25(OH)2D3 for 24 hrs |
Permissive
Robust
|
Homo sapiens |
GSE124032
...
|
MA0019.1
...
|
| CEBPA |
bone marrow-derived macrophages |
Sex: male; Strain:C57Bl/6EiJ; Treatment: KLA for 1 hr; Source: thioglycollate elicited macrophage cells; |
Permissive
Robust
|
Mus musculus |
GSE111854
...
|
MA0019.1
...
|
| CEBPA |
bone marrow-derived macrophages |
Sex: male; Strain:C57Bl/6EiJ; Treatment: PBS (Veh); Source: thioglycollate elicited macrophage cells; |
Permissive
Robust
|
Mus musculus |
GSE111854
...
|
MA0019.1
...
|
| CEBPA |
mesenchymal stem cells-derived adipocytes |
|
Permissive
Robust
|
Homo sapiens |
GSE24326
...
|
MA0019.1
...
|
| CEBPA |
hematopoietic stem cells |
|
Permissive
Robust
|
Mus musculus |
GSE43007
...
|
MA0019.1
...
|
| CEBPA |
haematopoietic progenitors |
|
Permissive
Robust
|
Mus musculus |
GSE43007
...
|
MA0019.1
...
|
| CEBPA |
B-cells |
|
Permissive
|
Mus musculus |
GSE52373
...
|
MA0019.1
...
|
| CEBPA |
haematopoietic progenitors |
|
Permissive
Robust
|
Mus musculus |
GSE47003
...
|
MA0019.1
...
|
| CEBPA |
hepatocytes |
|
Permissive
Robust
|
Mus musculus |
GSE17067
...
|
MA0019.1
...
|
| CEBPA |
3T3-L1-derived adipocytes |
|
Permissive
Robust
|
Mus musculus |
GSE17067
...
|
MA0019.1
...
|
| CEBPA |
brown preadipocytes |
|
Permissive
|
Mus musculus |
GSE50416
...
|
MA0019.1
...
|
| CEBPA |
brown preadipocytes |
|
Permissive
Robust
|
Mus musculus |
GSE50416
...
|
MA0019.1
...
|
| CEBPA |
BMDM (bone marrow-derived macrophages) |
|
Permissive
Robust
|
Mus musculus |
GSE50565
...
|
MA0019.1
...
|
| CEBPA |
BV-2 (brain microglial cells) |
|
Permissive
Robust
|
Mus musculus |
GSE54443
...
|
MA0019.1
...
|
| CEBPA |
hematopoietic progenitors |
|
Permissive
Robust
|
Mus musculus |
GSE58361
...
|
MA0019.1
...
|
| CEBPA |
leukemic bone marrow |
|
Permissive
Robust
|
Mus musculus |
GSE55850
...
|
MA0019.1
...
|
| CEBPA |
X18.1.1 (acute myeloid leukemia) |
|
Permissive
Robust
|
Mus musculus |
GSE63317
...
|
MA0019.1
...
|
| CEBPA |
hepatocytes |
|
Permissive
Robust
|
Mus musculus |
GSE65167
...
|
MA0019.1
...
|
| CEBPA |
acute myeloid leukemia |
|
Permissive
Robust
|
Mus musculus |
GSE66122
...
|
MA0019.1
...
|
| CEBPA |
liver |
|
Permissive
Robust
|
Mus musculus |
GSE70716
...
|
MA0019.1
...
|
| CEBPA |
B-cells |
|
Permissive
|
Mus musculus |
GSE71215
...
|
MA0019.1
...
|
| CEBPA |
bone marrow-derived mesenchymal stem cells |
|
Permissive
Robust
|
Mus musculus |
GSE79813
...
|
MA0019.1
...
|
| CEBPA |
brown preadipocytes |
|
Permissive
Robust
|
Mus musculus |
GSE76619
...
|
MA0019.1
...
|
| CEBPA |
brown preadipocytes |
|
Permissive
Robust
|
Mus musculus |
GSE76619
...
|
MA0019.1
...
|
| CEBPA |
Hoxb8-FL |
|
Permissive
Robust
|
Mus musculus |
GSE84328
...
|
MA0019.1
...
|
| CEBPA |
SKH1 (chronic myelogenous leukemia, BCR-ABL1 positive) |
|
Permissive
|
Homo sapiens |
GSE87283
...
|
MA0019.1
...
|
| CEBPA |
MV-4-11 (Childhood acute monocytic leukemia) |
|
Permissive
Robust
|
Homo sapiens |
GSE88746
...
|
MA0019.1
...
|
| CEBPA |
embryonic fibroblasts |
|
Permissive
Robust
|
Mus musculus |
GSE90893
...
|
MA0019.1
...
|
| CEBPA |
embryonic fibroblasts expressing OSKM for 48h |
|
Permissive
|
Mus musculus |
GSE90893
...
|
MA0019.1
...
|
| CEBPA |
liver |
|
Permissive
Robust
|
Mus musculus |
GSE22078
...
|
MA0019.1
...
|
| CEBPA |
HepG2 (hepatoblastoma) |
|
Permissive
Robust
|
Homo sapiens |
ENCSR142IGM
|
MA0019.1
...
|
| CEBPA |
MOLM-13(acute monocytic leukemia(AML), Homo sapiens) |
|
Permissive
Robust
|
Homo sapiens |
GSE120063
...
|
MA0019.1
|
| CEBPA |
U937 (adult acute monocytic leukemia) |
|
Permissive
Robust
|
Homo sapiens |
GSE120063
...
|
MA0019.1
...
|
| CEBPA |
Kasumi-1 (acute myeloblastic leukemia) |
|
Permissive
Robust
|
Homo sapiens |
GSE114642
...
|
MA0019.1
...
|
| CEBPA |
HepG2 (hepatoblastoma) |
|
Permissive
Robust
|
Homo sapiens |
ERP000209
|
MA0102.4
|
| CEBPA |
liver |
|
Permissive
Robust
|
Homo sapiens |
ERP002306
|
MA0102.4
|
| CEBPA |
U937 (adult acute monocytic leukemia) |
|
Permissive
Robust
|
Homo sapiens |
ERP008568
|
MA0102.4
|
| CEBPA |
SGBS (Simpson Golabi Behmel syndrome type 1 adipocytes) |
|
Permissive
Robust
|
Homo sapiens |
GSE41629
|
MA0102.4
|
| CEBPA |
Kasumi-1 (acute myeloblastic leukemia) |
SICTR |
Permissive
|
Homo sapiens |
GSE60130
|
MA0102.4
|
| CEBPA |
Kasumi-1 (acute myeloblastic leukemia) |
SIRUNX1ETO |
Permissive
Robust
|
Homo sapiens |
GSE60130
|
MA0102.4
|
